|

To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

RECRUITINGPhase 2Sponsored by Hyundai Pharm
Actively Recruiting
PhasePhase 2
SponsorHyundai Pharm
Started2024-12-12
Est. completion2025-03-31
Eligibility
Age19 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06647550

Summary

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Eligibility

Age: 19 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening.

Exclusion Criteria:

* Type 1 diabetes or another immune-mediated diabetes syndrome
* BMI: \> 40 kg/m2
* C-peptide: \< 0.5ng/mL

Conditions2

DiabetesType 2 Diabetes Mellitus (T2DM)

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.